Ascendis Pharma A/S
As of the edition of 20 October 2026, Ascendis Pharma A/S runs 4 drugs, 3 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 7 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Palopegteriparatide | Ends 2037 (patent) | 3 |
| Navepegritide | Ends 2037 (patent) | 1 |
| Lonapegsomatropin | Ends 2033 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Ascendis Pharma A/S needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Hormones: 11 trials led
- Bones, joints and muscles: 10 trials led
- Inherited and neonatal: 7 trials led